Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial
单位：[1]Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK[2]Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK[3]China-Japan Friendship Hospital, Beijing, China[4]Diabetes Research Group eV at Munich Helmholtz Centre, Munich, Germany[5]Department of Medicine K2, Karolinska Institute, Stockholm, Sweden
Aims: Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in patients with coronary heart disease (CHD) and IGT randomised to acarbose or placebo. Methods: Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up. Results: During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64-1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74-1.10, P = 0.32). Conclusions: Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF. (c) 2020 Elsevier B.V. All rights reserved.
第一作者单位：[1]Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
通讯作者：
通讯机构：[1]Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK[*1]Diabetes Trials Unit (OCDEM), Churchill Hospital, Oxford OX3 7LJ, UK.
推荐引用方式(GB/T 7714)：
Wamil Malgorzata,McMurray John J. V.,Scott Charles A. B.,et al.Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial[J].DIABETES RESEARCH and CLINICAL PRACTICE.2020,170:doi:10.1016/j.diabres.2020.108488.
APA：
Wamil, Malgorzata,McMurray, John J. V.,Scott, Charles A. B.,Coleman, Ruth L.,Sun, Yihong...&Holman, Rury R..(2020).Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.DIABETES RESEARCH and CLINICAL PRACTICE,170,
MLA：
Wamil, Malgorzata,et al."Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial".DIABETES RESEARCH and CLINICAL PRACTICE 170.(2020)
